{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:52:41Z","timestamp":1793303561047,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["13\/RC\/2073_P2"],"award-info":[{"award-number":["13\/RC\/2073_P2"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016259","name":"Viatris Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jconrel.2025.01.035","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T11:33:35Z","timestamp":1739100815000},"page":"375-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"C","title":["Albumin-based delivery systems: Recent advances, challenges, and opportunities"],"prefix":"10.1016","volume":"380","author":[{"given":"Gillian","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.01.035_bb0005","article-title":"Albumin: source, preparation, determination, applications, and prospects","volume":"8","author":"Hutapea","year":"2023","journal-title":"J. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0010","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12257-019-0512-9","article-title":"Albumin: an emerging opportunity in drug delivery","volume":"25","author":"Rahimizadeh","year":"2020","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3389\/fchem.2021.746646","article-title":"Recent advancements in serum albumin-based nanovehicles toward potential cancer diagnosis and therapy","volume":"9","author":"Shen","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1172\/JCI101514","article-title":"Chemical, clinical and immunological studies on products of human plasma fractionation VII. Concentrated human serum albumin","volume":"23","author":"Janeway","year":"1944","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0025","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0030","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3390\/jcm9113634","article-title":"Recent updates and advances in the use of glycated albumin for the diagnosis and monitoring of diabetes and renal, cerebro- and cardio-metabolic diseases","volume":"9","author":"Giglio","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0035","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/17425247.2022.2134341","article-title":"Current trends in the use of human serum albumin for drug delivery in cancer","volume":"19","author":"Paul","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol. Cell Ther."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0045","author":"Grifols USA LLC"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0050","author":"Takeda Pharmaceuticals America Inc"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0055","author":"Biologic Licensing Application"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0060","unstructured":"Biologic Licensing Application, Human Albumin Grifols Labelling Information, (2022). https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ad5163c6-c2c8-4356-a704-ddbd38bf997b#:\u223c:text=and%20the%20indication.-,Human%20Albumin%20Grifols%2025%25%20is%20a%20solution%20containing%20250%20g,to%20any%20of%20the%20excipients. (accessed May 4, 2023)."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0065","author":"Octapharma USA, Inc"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0070","author":"CryoLife Inc"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0075","series-title":"BioGlue\u00ae Surgical Adhesive Syringe Instructions for Use","author":"Cryolife Inc","year":"2019"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0080","series-title":"PROGEL\u2122 Pleural Air Leak Sealant Package Insert","author":"Neomend Inc","year":"2015"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0085","series-title":"PreveLeak\u2122 Summary of Safety and Effectiveness Data","author":"Mallinckrodt Pharma","year":"2017"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0090","series-title":"PreveLeak\u2122 Instructions for Use","author":"Baxter International Inc","year":"2021"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0095","series-title":"Tridyne\u2122 Summary of Safety and Effectiveness Data","author":"Neomend Inc","year":"2016"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0022-2860(02)00256-9","article-title":"Interaction of drugs with bovine and human serum albumin","volume":"614","author":"Su\u0142kowska","year":"2002","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/BF01733780","article-title":"Pharmacokinetics of methimazole in humans","volume":"63","author":"Hengstmann","year":"1985","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1210\/jcem-41-2-362","article-title":"Pharmacodynamics of propylthiouracil in normal and hyperthyroid subjects after a single oral dose","volume":"41","author":"McMurry","year":"1975","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0005-2795(80)90123-3","article-title":"The role of albumin conformation in the binding of diazepam to human serum albumin","volume":"626","author":"Wilting","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0120","series-title":"Epilepsy","author":"Ashworth","year":"1985"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0125","doi-asserted-by":"crossref","first-page":"22804","DOI":"10.1074\/jbc.M100575200","article-title":"Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I","volume":"276","author":"Petitpas","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0130","article-title":"Role of binding in distribution of furosemide: where is nonrenal clearance?","volume":"42","author":"Branch","year":"1983","journal-title":"Fed. Proc."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0140","doi-asserted-by":"crossref","DOI":"10.2147\/vhrm.2006.2.3.277","article-title":"Insulin detemir in the treatment of type 1 and type 2 diabetes","volume":"2","author":"Philips","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.regpep.2010.05.008","article-title":"Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes","volume":"164","author":"Werner","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0155","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1039\/D0RA01002B","article-title":"Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid","volume":"10","author":"Tang","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173650","article-title":"Albumin-binding domain extends half-life of glucagon-like peptide-1","volume":"890","author":"Tan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0170","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0175","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.035_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF\u03b1 NANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2014.03.013","article-title":"A clinical update of using albumin as a drug vehicle - a commentary","volume":"190","author":"Kratz","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":"SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients","volume":"2","author":"Desai","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0210","doi-asserted-by":"crossref","DOI":"10.1021\/bc00017a001","article-title":"Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo","volume":"3","author":"Maeda","year":"1992","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0215","article-title":"Technetium-99m-labeled autologous serum albumin: a personal-exclusive source of serum component","volume":"2011","author":"Wang","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.01.035_bb0220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0225","article-title":"Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0230","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0240","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0245","first-page":"393","article-title":"Paclitaxel (Taxol)","volume":"135","author":"Rowinsky","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0250","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0255","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4005","article-title":"Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)","volume":"31","author":"Von Hoff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0260","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0265","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14737167.2018.1464394","article-title":"An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study","volume":"18","author":"Lazzaro","year":"2018","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0270","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1078155214556008","article-title":"Abraxane\u00ae versus taxol\u00ae for patients with advanced breast cancer: a prospective time and motion analysis from a chinese health care perspective","volume":"22","author":"Dranitsaris","year":"2014","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0275","author":"Bristol Myers Squibb"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0280","article-title":"Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of p-gp","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0285","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123011","article-title":"Albumin-based nanoparticles for the delivery of doxorubicin in breast cancer","volume":"13","author":"Prajapati","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202104136","article-title":"A mannosylated, PEGylated albumin as a drug delivery system for the treatment of cancer stroma cells","volume":"31","author":"Mizuta","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.035_bb0300","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41551-022-00949-4","article-title":"Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours","volume":"6","author":"Schaal","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.035_bb0305","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.molpharmaceut.2c00297","article-title":"Nafamostat mesylate in combination with the mouse amino-terminal fragment of urokinase-human serum albumin improves the treatment outcome of triple-negative breast cancer therapy","volume":"20","author":"Zhou","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100778","article-title":"Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance","volume":"58","author":"Valente","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0320","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.2c00698","article-title":"Developing a copper(II) agent based on his-146 and his-242 residues of human serum albumin nanoparticles: integration to overcome cisplatin resistance and inhibit the metastasis of nonsmall cell lung cancer","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0325","doi-asserted-by":"crossref","first-page":"29495","DOI":"10.1021\/acsomega.2c04096","article-title":"Preparation of fetal bovine serum-copper phosphate hybrid particles under cell culture conditions for cancer cell treatment","volume":"7","author":"Mochizuki","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0330","doi-asserted-by":"crossref","DOI":"10.1186\/s12938-019-0624-7","article-title":"Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation","volume":"18","author":"Qu","year":"2019","journal-title":"Biomed. Eng. Online"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0335","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cbic.201800201","article-title":"Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery","volume":"19","author":"Zhao","year":"2018","journal-title":"ChemBioChem"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0340","article-title":"The albumin-binding domain as a scaffold for protein engineering","volume":"6","author":"Nilvebrant","year":"2013","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201804452","article-title":"Conjugate of doxorubicin to albumin-binding peptide outperforms aldoxorubicin","volume":"15","author":"Yousefpour","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0350","article-title":"A pH-Activatable copper-biomineralized proenzyme for synergistic Chemodynamic\/chemo-immunotherapy against aggressive cancers","volume":"35","author":"Li","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.140440","article-title":"BSA-magnetite nanotorpedo for safe and efficient delivery of chemotherapy drugs","volume":"454","author":"Zhao","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0360","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jconrel.2024.06.067","article-title":"Controlled release of manganese and magnesium ions by microsphere-encapsulated hydrogel enhances cancer immunotherapy","volume":"372","author":"Ma","year":"2024","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.035_bb0365","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41571-020-0410-2","article-title":"Clinical development and potential of photothermal and photodynamic therapies for cancer","volume":"17","author":"Li","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0370","doi-asserted-by":"crossref","first-page":"13818","DOI":"10.1021\/acsanm.1c03209","article-title":"Bovine serum albumin-encapsulated ultrasmall gold nanoclusters for photodynamic therapy of tumors","volume":"4","author":"Geng","year":"2021","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0375","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1039\/C9BM01192G","article-title":"A near infrared light-triggered human serum albumin drug delivery system with coordination bonding of indocyanine green and cisplatin for targeting photochemistry therapy against oral squamous cell cancer","volume":"7","author":"Wang","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0380","doi-asserted-by":"crossref","first-page":"19370","DOI":"10.1038\/srep19370","article-title":"A biocompatible and biodegradable protein hydrogel with green and red autofluorescence: preparation, characterization and in vivo biodegradation tracking and modeling","volume":"6","author":"Ma","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114237","article-title":"Deciphering albumin-directed drug delivery by imaging","volume":"185","author":"Hu","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0390","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jconrel.2022.08.054","article-title":"Self-activated arsenic manganite nanohybrids for visible and synergistic thermo\/immuno-arsenotherapy","volume":"350","author":"Zhai","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0395","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0400","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2337\/ds20-0033","article-title":"Injection-site nodules associated with once-weekly subcutaneous administration of semaglutide","volume":"34","author":"Hearn","year":"2021","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.09.003","article-title":"Challenges and innovations of drug delivery in older age","volume":"135","author":"Khan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0410","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches","volume":"157","author":"Brayden","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0415","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","article-title":"A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0420","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12847","article-title":"Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials","volume":"70","author":"Xue","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0425","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0430","article-title":"Recombinant fusion of glucagon-like peptide-1 and an albumin binding domain provides glycemic control for a week in diabetic mice","volume":"3","author":"Yousefpour","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0435","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","article-title":"A recombinant human glucagon-like peptide (GLP)-1\u2013albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor\u2013dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0440","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jconrel.2020.05.036","article-title":"Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects","volume":"324","author":"Watanabe","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0445","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0450","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial, the","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0455","author":"Lilly USA LLC"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0465","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2020.08.005","article-title":"Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin","volume":"327","author":"Azevedo","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0470","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Knudsen Sand","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0475","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0480","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0485","first-page":"1","article-title":"Historical perspective","author":"Peters","year":"1995","journal-title":"All about Albumin"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0490","first-page":"54","article-title":"Prognostic impact of follow-up serum albumin after acute myocardial infarction","volume":"8","author":"Yoshioka","year":"2021","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0495","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MCA.0000000000000362","article-title":"Evaluation of thiol levels, thiol\/disulfide homeostasis and their relation with inflammation in cardiac syndrome X","volume":"27","author":"Altiparmak","year":"2016","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0500","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/oxfordjournals.aje.a116030","article-title":"The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial","volume":"134","author":"Kuller","year":"1991","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.879812","article-title":"Early combination of albumin with crystalloid administration might reduce mortality in patients with cardiogenic shock: an over 10-year intensive care survey","volume":"9","author":"Zou","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0510","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133746","article-title":"Pharmaceutical novel solid forms of milrinone with advanced physicochemical properties","volume":"1269","author":"Giri","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0520","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/ph14070697","article-title":"Albumin nanoparticle formulation for heart-targeted drug delivery: in vivo assessment of congestive heart failure","volume":"14","author":"Lomis","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0525","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/0006-2952(89)90497-8","article-title":"Mechanism by which warfarin binds to human serum albumin: stopped-flow kinetic experiments with two large fragments of albumin","volume":"38","author":"Bos","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0530","doi-asserted-by":"crossref","DOI":"10.1039\/D0SM00977F","article-title":"Synthesis and characterization of photocrosslinkable albumin-based hydrogels for biomedical applications","volume":"16","author":"Lantigua","year":"2020","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0535","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0540","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.actbio.2022.04.021","article-title":"Preclinical validation of silibinin\/albumin nanoparticles as an applicable system against acute liver injury","volume":"146","author":"Ding","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12040341","article-title":"Interaction of lipoplex with albumin enhances gene expression in hepatitis mice","volume":"12","author":"Yoshikawa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/ph14050408","article-title":"Polymerized albumin receptor of hepatitis b virus for evading the reticuloendothelial system","volume":"14","author":"Takagi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0555","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1021\/acs.molpharmaceut.8b00408","article-title":"Liver-targeted co-delivery of entecavir and glycyrrhetinic acid based on albumin nanoparticle to enhance the accumulation of entecavir","volume":"15","author":"He","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0560","doi-asserted-by":"crossref","DOI":"10.1042\/cs0950459","article-title":"Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion","volume":"95","author":"Quinlan","year":"1998","journal-title":"Clin. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0565","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay7148","article-title":"Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers","volume":"6","author":"Dawulieti","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0570","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax7964","article-title":"Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke","volume":"5","author":"Zhang","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0575","article-title":"Temperature induced changes in blood acid base status: donnan r(cl) and red cell volume","volume":"40","author":"Reeves","year":"1976","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/nnano.2014.17","article-title":"Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils","volume":"9","author":"Wang","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0585","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0590","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijantimicag.2019.03.004","article-title":"Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states","volume":"54","author":"Goldstein","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0595","article-title":"Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0600","doi-asserted-by":"crossref","DOI":"10.1021\/acsami.9b15107","article-title":"Albumin broadens the antibacterial capabilities of nonantibiotic small molecule-capped gold nanoparticles","volume":"11","author":"Sun","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10010057","article-title":"Enhanced antimicrobial and antibiofilm effect of new colistin-loaded human albumin nanoparticles","volume":"10","author":"Scutera","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0610","doi-asserted-by":"crossref","DOI":"10.1097\/ICL.0b013e3181becd3c","article-title":"In vitro adsorption of tear proteins to hydroxyethyl methacrylate-based contact lens materials","volume":"35","author":"Carney","year":"2009","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/polym13132051","article-title":"Albumin acts as a lubricant on the surface of hydrogel and silicone hydrogel contact lenses","volume":"13","author":"Su","year":"2021","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0620","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00006324-199801000-00021","article-title":"Modulation of bacterial adhesion to hydrogel contact lenses by albumin","volume":"75","author":"Taylor","year":"1998","journal-title":"Optom. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0625","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41587-022-01408-w","article-title":"Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts","volume":"41","author":"Rafat","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0630","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clae.2008.05.004","article-title":"Albumin adsorption to contact lens materials: a review","volume":"31","author":"Luensmann","year":"2008","journal-title":"Cont. Lens Anterior Eye"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.820260403","article-title":"Albumin-binding surfaces for implantable devices","volume":"26","author":"Keogh","year":"1992","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0640","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.1987.tb33032.x","article-title":"Influence of endogenous albumin binding on blood-material interactions","volume":"516","author":"Eberhart","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0645","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1021\/acsabm.2c00109","article-title":"Mass spectrometry, structural analysis, and anti-inflammatory properties of photo-cross-linked human albumin hydrogels","volume":"5","author":"Sharifi","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmst.2020.02.006","article-title":"In vitro and in vivo biodegradation and biocompatibility of an MMT\/BSA composite coating upon magnesium alloy AZ31","volume":"47","author":"Wang","year":"2020","journal-title":"J. Mater. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0655","doi-asserted-by":"crossref","DOI":"10.1002\/term.2803","article-title":"Serum albumin-coated bone allograft (BoneAlbumin) results in faster bone formation and mechanically stronger bone in aging rats","volume":"13","author":"Horv\u00e1thy","year":"2019","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.638577","article-title":"Antibacterial albumin-tannic acid coatings for scaffold-guided breast reconstruction","volume":"9","author":"Cometta","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0665","article-title":"Label-free serum albumin nanoparticles for bioimaging and Trojan horse-like drug delivery","volume":"7","author":"Patra","year":"2022","journal-title":"J. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmmm.2018.10.135","article-title":"Human serum albumin as an effective coating for hydrophobic photosensitizes immobilization on magnetic nanoparticles","volume":"475","author":"Ostroverkhov","year":"2019","journal-title":"J. Magn. Magn. Mater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106749","article-title":"Bovine serum albumin-encapsulated gold nanoclusters-Cu2+ synergize and promote calcein chemiluminescence for glutathione detection in human whole blood","volume":"170","author":"Huang","year":"2021","journal-title":"Microchem. J."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0680","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0685","first-page":"930","article-title":"Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance","volume":"3","author":"Hassanin","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0690","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.actbio.2022.11.058","article-title":"Emerging albumin hydrogels as personalized biomaterials","volume":"157","author":"Kong","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0695","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bsheal.2022.12.004","article-title":"Hyperoncotic human albumin solutions for intravenous fluid therapy: effectiveness of pathogen safety and purification methods, and clinical safety","volume":"5","author":"Simon","year":"2023","journal-title":"Biosaf. Health"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0700","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2018.06.024","article-title":"Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?","volume":"131","author":"M\u00fchlebach","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0705","series-title":"Classifying Approved New Drug Products and Drug-Device Combination Products as Complex Products for Generic Drug Development Purposes (MAPP 5240.10)","author":"The Food and Drug Administration (FDA) Office of Generic Drugs","year":"2022"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0710","series-title":"De Novo Classification Process (Evaluation of Automatic Class III Designation)","author":"The Food and Drug Administration (FDA), Office of Operations","year":"2021"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0715","author":"The International Council for Harmonization (ICH)"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0720","author":"International Organization for Standardization (ISO)"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0725","author":"The United States Pharmacopeial Convention"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0730","author":"Council of Europe"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0735","article-title":"Regulation (EU) 2017\/745 of the European Parliament and of the council of 5 April 2017 on medical devices, amending directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and repealing Council Directives 90\/385\/EEC and 93\/42\/EEC","author":"European Parliament and tThe Council of the European Union","year":"2017","journal-title":"Off. J. Eur. Union"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0740","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.0c05208","article-title":"Analytical methods for characterization of nanomaterial surfaces","volume":"93","author":"Jayawardena","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0745","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.9b00839","article-title":"Investigations of albumin-insulin detemir complexes using molecular dynamics simulations and free energy calculations","volume":"17","author":"Ryberg","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0750","doi-asserted-by":"crossref","DOI":"10.1038\/s41580-019-0163-x","article-title":"Advances in protein structure prediction and design","volume":"20","author":"Kuhlman","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0755","article-title":"Molecular modeling prediction of albumin-based nanoparticles and experimental preparation, characterization, and in-vitro release kinetics of prednisolone from the nanoparticles","volume":"64","author":"Kaboli","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0760","doi-asserted-by":"crossref","DOI":"10.1116\/1.4992101","article-title":"Molecular modeling to predict peptide accessibility for peptide-functionalized hydrogels","volume":"12","author":"Li","year":"2017","journal-title":"Biointerphases"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0765","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jconrel.2021.03.005","article-title":"Not only in silico drug discovery: molecular modeling towards in silico drug delivery formulations","volume":"332","author":"Casalini","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0770","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2008.0508.focus","article-title":"Challenges in the computational design of proteins","volume":"6","author":"Su\u00e1rez","year":"2009","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0775","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2044744","article-title":"Computational models for studying physical instabilities in high concentration biotherapeutic formulations","volume":"14","author":"Blanco","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0780","author":"European Commission"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0785","doi-asserted-by":"crossref","DOI":"10.1021\/acs.estlett.2c00446","article-title":"Greener pharmaceuticals for more sustainable healthcare","volume":"9","author":"Moermond","year":"2022","journal-title":"Environ. Sci. Technol. Lett."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0790","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/toxsci\/kfw028","article-title":"Setting occupational exposure limits for genotoxic substances in the pharmaceutical industry","volume":"151","author":"Barle","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0795","series-title":"Nanoparticle Compositions of Albumin and Paclitaxel, AU2013370955B2","author":"Abraxis BioScience LLC","year":"2018"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0800","series-title":"Nanoparticles of Paclitaxel and Albumin in Combination With Bevacizumab Against Cancer, EP2481405A1","author":"Abraxis BioScience LLC","year":"2016"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.126362","article-title":"Non-covalent assembly of albumin nanoparticles by hydroxyl radical: a possible mechanism of the nab technology and a one-step green method to produce protein nanocarriers","volume":"404","author":"Luo","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0810","article-title":"A novel preparative method for nanoparticle albumin-bound paclitaxel with high drug loading and its evaluation both in vitro and in vivo","volume":"16","author":"Gao","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03846","article-title":"Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer","volume":"6","author":"Soni","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0820","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202104441","article-title":"3D printing of bioinspired alginate-albumin based instant gel ink with electroconductivity and its expansion to direct four-axis printing of hollow porous tubular constructs without supporting materials","volume":"31","author":"Janarthanan","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0825","doi-asserted-by":"crossref","DOI":"10.1111\/jphp.12134","article-title":"Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells","volume":"66","author":"Suen","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0830","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202001146","article-title":"A microfluidic co-flow route for human serum albumin-drug\u2013nanoparticle assembly","volume":"26","author":"Hakala","year":"2020","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111854","article-title":"Microfluidic production of polymeric core-shell microspheres for the delayed pulsatile release of bovine serum albumin as a model antigen","volume":"13","author":"van der Kooij","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0840","series-title":"Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia","author":"Alexion (LogicBio Therapeutics Inc.)","year":"2020"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0845","author":"Angiocrine Bioscience"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0850","author":"Fondazione Telethon"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0855","author":"Asahi Kasei Pharma Corporation"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0860","author":"Nordic Urothelial Cancer Group"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0865","author":"Assiut University"},{"key":"10.1016\/j.jconrel.2025.01.035_bb0870","article-title":"Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.jconrel.2025.01.035_bb0875","article-title":"Drugs, devices, and the FDA: part 2: an overview of approval processes: FDA approval of medical devices","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:54:58Z","timestamp":1770141298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":172,"alternative-id":["S0168365925000458"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin-based delivery systems: Recent advances, challenges, and opportunities","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}